Meeting
2014 ASCO Annual Meeting
Nintedanib plus pemetrexed/cisplatin followed by maintenance nintedanib for unresectable malignant pleural mesothelioma (MPM): An international, multicenter, randomized, double-blind, placebo-controlled phase II study.
Authors
Giorgio V. Scagliotti
Department of Clinical and Biological Sciences, University of Turin, S. Luigi Hospital, Torino, Italy
Giorgio V. Scagliotti , Natasha B. Leighl , Anna K. Nowak , Nick Pavlakis , Sanjay Popat , Jens Benn Sorensen , Jose Barrueco , Rolf Kaiser , Arsene-Bienvenu Loembe , Martha Mueller , Ute von Wangenheim , Martin Reck
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer - Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Mesothelioma
Clinical Trial Registration Number
NCT01907100
Citation
J Clin Oncol 32:5s, 2014 (suppl; abstr TPS7612)
DOI
10.1200/jco.2014.32.15_suppl.tps7612
Abstract #
TPS7612
Poster Bd #
218A
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
Lume-meso: A double-blind, randomized, phase II/III study of nintedanib (N) + pemetrexed (P)/cisplatin (C) followed by maintenance N versus placebo + P/C followed by maintenance placebo for patients with unresectable malignant pleural mesothelioma (MPM).
First Author: Giorgio V. Scagliotti
Poster
2018 ASCO Annual Meeting
SWOG S0905: A randomized phase II study of cediranib versus placebo in combination with cisplatin and pemetrexed in chemonaive patients with malignant pleural mesothelioma.
First Author: Anne S. Tsao
Poster
2017 ASCO Annual Meeting
ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.
First Author: Peter Wojciech Szlosarek
Poster
2016 ASCO Annual Meeting
A randomized, placebo-controlled study of amatuximab in combination with pemetrexed and cisplatin (P/C) as front-line therapy for subjects with malignant pleural mesothelioma (MPM).
First Author: Raffit Hassan